Clinical Utility of Random Anti-Tumor Necrosis Factor Drug-Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis

Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis

(2014) Motoaki Hoshino et al.   Modern Rheumatology

Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort

(2014) James Bluett et al.   RHEUMATOLOGY

Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation

(2014) Jacqueline E Paramarta et al.   ARTHRITIS RESEARCH & THERAPY

Key findings towards optimising adalimumab treatment: the concentration–effect curve

(2013) Mieke F Pouw et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study

(2013) S.K. Mahil et al.   BRITISH JOURNAL OF DERMATOLOGY

The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases

(2013) M. Jani et al.   RHEUMATOLOGY

Immunogenicity of Monoclonal Antibodies Against Tumor Necrosis Factor Used in Chronic Immune-Mediated Inflammatory Conditions

(2013) Jose Ramon Maneiro et al.   JAMA Internal Medicine

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

(2012) Fabien B Vincent et al.   ANNALS OF THE RHEUMATIC DISEASES

Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner

(2012) Charlotte L Krieckaert et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation

(2012) Pauline A van Schouwenburg et al.   ANNALS OF THE RHEUMATIC DISEASES

The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis

(2012) Sandra Garcês et al.   ANNALS OF THE RHEUMATIC DISEASES

Immunogenicity to Biologics: Mechanisms, Prediction and Reduction

(2012) Swaminathan Sethu et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity

(2012) Charlotte L. Krieckaert et al.   ARTHRITIS AND RHEUMATISM

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

(2011) A Jamnitski et al.   ANNALS OF THE RHEUMATIC DISEASES

Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?

(2011) Klaus Bendtzen   ARTHRITIS AND RHEUMATISM

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

(2011) Geertje M. Bartelds   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Differential effect of drug interference in immunogenicity assays

(2011) Margreet H. Hart et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF B signalling pathways

(2010) C. Potter et al.   ANNALS OF THE RHEUMATIC DISEASES

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

(2010) A. Jamnitski et al.   ANNALS OF THE RHEUMATIC DISEASES

A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients

(2010) Pauline A. van Schouwenburg et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Immunoglobulin G4: an odd antibody

(2009) R. C. Aalberse et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

(2008) T R D J Radstake et al.   ANNALS OF THE RHEUMATIC DISEASES

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis

(2008) M K de Vries et al.   ANNALS OF THE RHEUMATIC DISEASES